Product Name :
PS-1145
Description:
PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.
CAS:
431898-65-6
Molecular Weight:
322.75
Formula:
C17H11ClN4O
Chemical Name:
N-6-chloro-9H-pyrido[3,4-b]indol-8-ylpyridine-3-carboxamide
Smiles :
O=C(NC1C=C(Cl)C=C2C=1NC1=CN=CC=C21)C1=CN=CC=C1
InChiKey:
JZRMBDHPALEPDM-UHFFFAOYSA-N
InChi :
InChI=1S/C17H11ClN4O/c18-11-6-13-12-3-5-20-9-15(12)21-16(13)14(7-11)22-17(23)10-2-1-4-19-8-10/h1-9,21H,(H,22,23)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.|Product information|CAS Number: 431898-65-6|Molecular Weight: 322.75|Formula: C17H11ClN4O|Chemical Name: N-6-chloro-9H-pyrido[3,4-b]indol-8-ylpyridine-3-carboxamide|Smiles: O=C(NC1C=C(Cl)C=C2C=1NC1=CN=CC=C21)C1=CN=CC=C1|InChiKey: JZRMBDHPALEPDM-UHFFFAOYSA-N|InChi: InChI=1S/C17H11ClN4O/c18-11-6-13-12-3-5-20-9-15(12)21-16(13)14(7-11)22-17(23)10-2-1-4-19-8-10/h1-9,21H,(H,22,23)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 20.83 mg/mL (64.54 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Quinidine Protocol |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|PS-1145 blocks TNFα-induced NF-κB activation in a dose- and time-dependent fashion in MM cells through inhibition of IκBα phosphorylation. Dexamethasone (Dex), which up-regulates IκBα protein, enhances blockade of NF-κB activation by PS-1145. PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis.Sotagliflozin supplier TNFα-induced intracellular adhesion molecule (ICAM)-1 expression on both RPMI8226 and MM.1S cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from bone marrow stromal cells (BMSCs) triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs.PMID:33190551 |In Vivo:|Administration of either Bortezomib or PS-1145 (50 mg/kg) results in a significant decrease in serum levels of all 3 cytokines that is nonsignificantly different from those in mice that underwent transplantation with TCD BM alone. PS1145 is injected intracerebroventricular (icv) as a pretreatment to block hypothalamic inflammation induced by IL-4 in adult male Wistar rats consuming a high-fat diet (HFD) over an 11-day period. The four groups of rats according to icv pretreatment/treatment condition are Veh/Veh, Veh/IL-4, PS1145/Veh, and PS1145/IL-4. Rats in the Veh/IL-4 group display increased weight gain on the HFD compared with the Veh/Veh group (PProducts are for research use only. Not for human use.|
